Assay Detail
Binding
CHEMBL4605643
Review assay metadata, readout intent, target linkage, and publication context from the same page.
Inhibition of human ABL1 assessed as residual activity using EAIYAAPFAKKK as substrate by [gamma-33P]-ATP assay
8
Total Activities
8
Compounds Tested
1
Activity Types
0
Assay Parameters
Assay Information
| Assay Type | Binding |
| Organism | Homo sapiens |
| Confidence | 9 — Direct single protein target |
| Curated By | Autocuration |
Publication
Accelerated Discovery of Novel Ponatinib Analogs with Improved Properties for the Treatment of Parkinson's Disease.
Activity Statistics
| Type | Count | Avg pChEMBL | Best pChEMBL |
|---|---|---|---|
| IC50 | 8 | 8.85 | 9.52 |
Compounds Tested
| Compound | Name | Phase | Activities | Best pChEMBL |
|---|---|---|---|---|
| CHEMBL4632471 | — | — | 1 | 9.52 |
| CHEMBL1171837 | PONATINIB | 4.0 | 1 | 9.51 |
| CHEMBL4642144 | — | — | 1 | 9.41 |
| CHEMBL4637502 | — | — | 1 | 9.19 |
| CHEMBL255863 | NILOTINIB | 4.0 | 1 | 8.26 |
| CHEMBL4638981 | — | — | 1 | 8.08 |
| CHEMBL4640297 | — | — | 1 | 8.00 |
| CHEMBL4633367 | — | — | 1 | - |
Activity Data
| Compound | Name | Type | Rel. | Value | Units | pChEMBL |
|---|---|---|---|---|---|---|
| CHEMBL4632471 | — | IC50 | = | 0.3 | nM | 9.52 |
| CHEMBL1171837 | PONATINIB | IC50 | = | 0.31 | nM | 9.51 |
| CHEMBL4642144 | — | IC50 | = | 0.39 | nM | 9.41 |
| CHEMBL4637502 | — | IC50 | = | 0.65 | nM | 9.19 |
| CHEMBL255863 | NILOTINIB | IC50 | = | 5.56 | nM | 8.26 |
| CHEMBL4638981 | — | IC50 | = | 8.31 | nM | 8.08 |
| CHEMBL4640297 | — | IC50 | = | 9.96 | nM | 8.00 |
| CHEMBL4633367 | — | IC50 | > | 30.0 | nM | - |